Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 4, pp 870–880 | Cite as

Gastrointestinal Tract Pathology in a BALB/c Niemann–Pick Disease Type C1 Null Mouse Model

  • Antony Cougnoux
  • Miyad Movassaghi
  • Jaqueline A. Picache
  • James R. Iben
  • Fatemeh Navid
  • Alexander Salman
  • Kyle Martin
  • Nicole Y. Farhat
  • Celine Cluzeau
  • Wei-Chia Tseng
  • Kathryn Burkert
  • Caitlin Sojka
  • Christopher A. Wassif
  • Niamh X. Cawley
  • Richard Bonnet
  • Forbes D. PorterEmail author
Original Article

Abstract

Background

Niemann–Pick disease, type C (NPC) is a rare lysosomal storage disorder characterized by progressive neurodegeneration, splenomegaly, hepatomegaly, and early death. NPC is caused by mutations in either the NPC1 or NPC2 gene. Impaired NPC function leads to defective intracellular transport of unesterified cholesterol and its accumulation in late endosomes and lysosomes. A high frequency of Crohn disease has been reported in NPC1 patients, suggesting that gastrointestinal tract pathology may become a more prominent clinical issue if effective therapies are developed to slow the neurodegeneration. The Npc1 nih mouse model on a BALB/c background replicates the hepatic and neurological disease observed in NPC1 patients. Thus, we sought to characterize the gastrointestinal tract pathology in this model to determine whether it can serve as a model of Crohn disease in NPC1.

Methods

We analyzed the gastrointestinal tract and isolated macrophages of BALB/cJ cNctr-Npc1m1N/J (Npc1/) mouse model to determine whether there was any Crohn-like pathology or inflammatory cell activation. We also evaluated temporal changes in the microbiota by 16S rRNA sequencing of fecal samples to determine whether there were changes consistent with Crohn disease.

Results

Relative to controls, Npc1 mutant mice demonstrate increased inflammation and crypt abscesses in the gastrointestinal tract; however, the observed pathological changes are significantly less than those observed in other Crohn disease mouse models. Analysis of Npc1 mutant macrophages demonstrated an increased response to lipopolysaccharides and delayed bactericidal activity; both of which are pathological features of Crohn disease. Analysis of the bacterial microbiota does not mimic what is reported in Crohn disease in either human or mouse models. We did observe significant increases in cyanobacteria and epsilon-proteobacteria. The increase in epsilon-proteobacteria may be related to altered cholesterol homeostasis since cholesterol is known to promote growth of this bacterial subgroup.

Conclusions

Macrophage dysfunction in the BALB/c Npc1/ mouse is similar to that observed in other Crohn disease models. However, neither the degree of pathology nor the microbiota changes are typical of Crohn disease. Thus, this mouse model is not a good model system for Crohn disease pathology reported in NPC1 patients.

Keywords

Niemann–Pick disease type C Gastrointestinal tract Microbiota Macrophage dysfunction Crohn disease 

Abbreviations

NPC1

Niemann–Pick disease, type C1

IBD

Inflammatory bowel disease

Notes

Acknowledgments

We thank Dr. Laetitia Dorso and Dr. Jerome Abadie (Oniris, Atlampole-La Chanterie, Nante, France) for the pathological analysis. We thank the NICHD Molecular genomic core for the 16S sequencing and analysis of the results.

Author’s contribution

AC and MM performed and analyzed the experiments. JAP, FN, AS, KM, NYF, CC, W-CT, KB, CS, CAW, and NXC provided experimental and technical support. JRI performed bioinformatics analysis. RB organized the pathological analysis and provided experimental advice. FDP provided experimental input. AC, MM, NXC, FN, RB, and FDP participated in the writing of the manuscript. All authors approved the final manuscript.

Funding

This work was supported by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. C.A.W. is an NIH/Oxford Scholar.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Vanier MT. Niemann–Pick disease type C. Orphanet J Rare Dis. 2010;5:16.  https://doi.org/10.1186/1750-1172-5-16.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stampfer M, Theiss S, Amraoui Y, et al. Niemann–Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8:35.  https://doi.org/10.1186/1750-1172-8-35.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Subramanian K, Balch WE. NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proc Natl Acad Sci USA. 2008;105:15223–15224.  https://doi.org/10.1073/pnas.0808256105.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yanjanin NM, Velez JI, Gropman A, et al. Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:132–140.  https://doi.org/10.1002/ajmg.b.30969.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Patterson MC. A riddle wrapped in a mystery: understanding Niemann–Pick disease, type C. Neurologist. 2003;9:301–310.  https://doi.org/10.1097/01.nrl.0000094627.78754.5b.CrossRefPubMedGoogle Scholar
  6. 6.
    Imrie J, Heptinstall L, Knight S, Strong K. Observational cohort study of the natural history of Niemann–Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol. 2015;15:257.  https://doi.org/10.1186/s12883-015-0511-1.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cologna SM, Cluzeau CV, Yanjanin NM, et al. Human and mouse neuroinflammation markers in Niemann–Pick disease, type C1. J Inherit Metab Dis. 2014;37:83–92.  https://doi.org/10.1007/s10545-013-9610-6.CrossRefPubMedGoogle Scholar
  8. 8.
    Bradbury A, Bagel J, Sampson M, et al. Cerebrospinal fluid calbindin D concentration as a biomarker of cerebellar disease progression in Niemann–Pick type C1 disease. J Pharmacol Exp Ther. 2016;358:254–261.  https://doi.org/10.1124/jpet.116.232975.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Alam MS, Getz M, Yi S, Kurkewich J, Safeukui I, Haldar K. Plasma signature of neurological disease in the monogenetic disorder Niemann–Pick type C. J Biol Chem. 2014;289:8051–8066.  https://doi.org/10.1074/jbc.M113.526392.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann–Pick C1 disease. Sci Transl Med. 2010;2:56ra81.  https://doi.org/10.1126/scitranslmed.3001417.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cluzeau CV, Watkins-Chow DE, Fu R, et al. Microarray expression analysis and identification of serum biomarkers for Niemann–Pick disease, type C1. Hum Mol Genet. 2012;21:3632–3646.  https://doi.org/10.1093/hmg/dds193.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Roszell BR, Tao J-Q, Yu KJ, et al. Pulmonary abnormalities in animal models due to Niemann–Pick type C1 (NPC1) or C2 (NPC2) disease. PLoS ONE. 2013;8:e67084.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Deutsch G, Muralidhar A, Le E, Borbon IA, Erickson RP. Extensive macrophage accumulation in young and old Niemann–Pick C1 model mice involves the alternative, M2, activation pathway and inhibition of macrophage apoptosis. Gene. 2016;578:242–250.  https://doi.org/10.1016/j.gene.2015.12.033.CrossRefPubMedGoogle Scholar
  14. 14.
    Peake KB, Hayashi H, Campenot R, Vance D, Vance J. Inflammation in the Niemann–Pick type-C brain. FASEB J. 2007;21:486.1.Google Scholar
  15. 15.
    Alam MS, Getz M, Safeukui I, et al. Genomic expression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder. PLoS ONE. 2012;7:e48273.  https://doi.org/10.1371/journal.pone.0048273.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kapur R, Donohue C, Jelinek D, Erickson RP. Amelioration of enteric neuropathology in a mouse model of Niemann–Pick C by Npc1 expression in enteric glia. J Neurosci Res. 2009;87:2994–3001.  https://doi.org/10.1002/jnr.22126.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jolliffe DS, Sarkany I. Niemann–Pick type III and Crohn’s disease. J R Soc Med. 1983;76:307–308.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Peneau A, Savoye G, Turck D, et al. Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2013;108:1647–1653.  https://doi.org/10.1038/ajg.2013.242.CrossRefPubMedGoogle Scholar
  19. 19.
    Steven L, Driver C. Niemann–pick disease type C and Crohn disease. Scott Med J. 2005;50:80–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Dickson I. Crohn’s disease: impaired bacterial clearance in IBD. Nat Rev Gastroenterol Hepatol. 2016;.  https://doi.org/10.1038/nrgastro.2016.55.Google Scholar
  21. 21.
    Schwerd T, Pandey S, Yang HT, et al. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn’s disease. Gut. 2016;.  https://doi.org/10.1136/gutjnl-2015-310382.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2016;.  https://doi.org/10.1016/S0140-6736(16)31711-1.Google Scholar
  23. 23.
    Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.CrossRefPubMedGoogle Scholar
  24. 24.
    Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2011;24:181–187.Google Scholar
  25. 25.
    Sarkar S, Carroll B, Buganim Y, et al. Impaired autophagy in the lipid-storage disorder Niemann–Pick type C1 disease. Cell Rep. 2013;5:1302–1315.  https://doi.org/10.1016/j.celrep.2013.10.042.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Suzuki M, Sugimoto Y, Ohsaki Y, et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann–Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J Neurosci. 2007;27:1879–1891.CrossRefPubMedGoogle Scholar
  27. 27.
    Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24:943–954.  https://doi.org/10.1111/j.1440-1746.2009.05854.x.CrossRefPubMedGoogle Scholar
  28. 28.
    Picache JA, Cologna SM, Yergey AL, Picard P, Chen C, Burkert KR, et al., eds. A label-free, mass spectrometry-based high throughput candidate drug screening assay: application to Smith–Lemli–Opitz syndrome. In: ASMS Conference; 2016; San Antonio.Google Scholar
  29. 29.
    DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72:5069–5072.  https://doi.org/10.1128/AEM.03006-05.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336.  https://doi.org/10.1038/nmeth.f.303.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010;.  https://doi.org/10.3791/1488.Google Scholar
  32. 32.
    Ravindran R, Loebbermann J, Nakaya HI, et al. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature. 2016;531:523–527.  https://doi.org/10.1038/nature17186.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Zavros Y, Eaton KA, Kang W, et al. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene. 2005;24:2354–2366.  https://doi.org/10.1038/sj.onc.1208407.CrossRefPubMedGoogle Scholar
  34. 34.
    Erben U, Loddenkemper C, Doerfel K, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–4576.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Pizarro TT, Arseneau KO, Bamias G, Cominelli F. Mouse models for the study of Crohn’s disease. Trends Mol Med. 2003;9:218–222.CrossRefPubMedGoogle Scholar
  36. 36.
    Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014;104:Unit 15 25.  https://doi.org/10.1002/0471142735.im1525s104.
  37. 37.
    Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn’s disease pathogenesis. Gastroenterology. 2010;139:1630–1641, 41 e1–2.  https://doi.org/10.1053/j.gastro.2010.07.006.
  38. 38.
    Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology. 2011;140:1738–1747.  https://doi.org/10.1053/j.gastro.2011.02.048.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sarkar S, Maetzel D, Korolchuk VI, Jaenisch R. Restarting stalled autophagy a potential therapeutic approach for the lipid storage disorder, Niemann–Pick type C1 disease. Autophagy. 2014;10:1137–1140.  https://doi.org/10.4161/auto.28623.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zhong CY, Sun WW, Ma Y, et al. Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice. Sci Rep. 2015;5:10512.  https://doi.org/10.1038/srep10512.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Martinez I, Brown AW, Walter J. Does host cholesterol metabolism impact the gut microbiota and why does it matter? Future Microbiol. 2013;8:571–573.  https://doi.org/10.2217/fmb.13.24.CrossRefPubMedGoogle Scholar
  42. 42.
    Gerard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 2013;3:14–24.  https://doi.org/10.3390/pathogens3010014.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392.  https://doi.org/10.1016/j.chom.2014.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Dawson RM. The toxicology of microcystins. Toxicon. 1998;36:953–962.CrossRefPubMedGoogle Scholar
  45. 45.
    Parra J, Klein AD, Castro J, et al. Npc1 deficiency in the C57BL/6J genetic background enhances Niemann–Pick disease type C spleen pathology. Biochem Biophys Res Commun. 2011;413:400–406.  https://doi.org/10.1016/j.bbrc.2011.08.096.CrossRefPubMedGoogle Scholar
  46. 46.
    Alzoghaibi MA. Neutrophil expression and infiltration into Crohn’s intestine. Saudi J Gastroenterol. 2005;11:63–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease–environmental factors. Hepato-gastroenterology. 2000;47:29–43.PubMedGoogle Scholar
  48. 48.
    Ardizzone S, Bollani S, Manzionna G, Bianchi Porro G. Inflammatory bowel disease approaching the 3rd millennium: pathogenesis and therapeutic implications? Eur J Gastroenterol Hepatol. 1999;11:27–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Baker PI, Love DR, Ferguson LR. Role of gut microbiota in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2009;3:535–546.  https://doi.org/10.1586/egh.09.47.CrossRefPubMedGoogle Scholar
  50. 50.
    Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol. 2015;1:154–170.  https://doi.org/10.1016/j.jcmgh.2015.01.006.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Maue RA, Burgess RW, Wang B, et al. A novel mouse model of Niemann–Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Hum Mol Genet. 2012;21:730–750.  https://doi.org/10.1093/hmg/ddr505.CrossRefPubMedGoogle Scholar
  52. 52.
    Praggastis M, Tortelli B, Zhang J, et al. A murine Niemann–Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. J Neurosci. 2015;35:8091–8106.  https://doi.org/10.1523/JNEUROSCI.4173-14.2015.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kaakoush NO, Mitchell HM, Man SM. Role of emerging Campylobacter species in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:2189–2197.  https://doi.org/10.1097/MIB.0000000000000074.CrossRefPubMedGoogle Scholar
  54. 54.
    Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5:400–404.  https://doi.org/10.4291/wjgp.v5.i4.400.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    D’Elios MM, Czinn SJ. Immunity, inflammation, and vaccines for Helicobacter pylori. Helicobacter. 2014;19 Suppl 1:19–26.  https://doi.org/10.1111/hel.12156.CrossRefPubMedGoogle Scholar
  56. 56.
    Mahendran V, Riordan SM, Grimm MC, et al. Prevalence of Campylobacter species in adult Crohn’s disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE. 2011;6:e25417.  https://doi.org/10.1371/journal.pone.0025417.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Jimenez-Soto LF, Rohrer S, Jain U, Ertl C, Sewald X, Haas R. Effects of cholesterol on Helicobacter pylori growth and virulence properties in vitro. Helicobacter. 2012;17:133–139.  https://doi.org/10.1111/j.1523-5378.2011.00926.x.CrossRefPubMedGoogle Scholar
  58. 58.
    McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother. 2011;55:2897–2904.  https://doi.org/10.1128/AAC.00016-11.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Jones-Hall YL, Kozik A, Nakatsu C. Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease. PLoS ONE. 2015;10:e0119441.  https://doi.org/10.1371/journal.pone.0119441.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–498.  https://doi.org/10.1016/j.cell.2009.09.033.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  • Antony Cougnoux
    • 1
  • Miyad Movassaghi
    • 1
  • Jaqueline A. Picache
    • 1
  • James R. Iben
    • 1
  • Fatemeh Navid
    • 2
  • Alexander Salman
    • 1
  • Kyle Martin
    • 1
  • Nicole Y. Farhat
    • 1
  • Celine Cluzeau
    • 1
  • Wei-Chia Tseng
    • 1
  • Kathryn Burkert
    • 1
  • Caitlin Sojka
    • 1
  • Christopher A. Wassif
    • 1
  • Niamh X. Cawley
    • 1
  • Richard Bonnet
    • 3
    • 4
  • Forbes D. Porter
    • 1
    Email author
  1. 1.Department of Health and Human Services, National Institutes of HealthEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentBethesdaUSA
  2. 2.Department of Health and Human Services, National Institutes of HealthNational Institute of Arthritis and Musculoskeletal and Skin DiseasesBethesdaUSA
  3. 3.Microbes, Inflammation, Intestin et Susceptibilité de l’Hôte (M2iSH), Inserm U1071, INRA USC2018Clermont Université, Université d’AuvergneClermont-FerrandFrance
  4. 4.Laboratoire de BactériologieCenter Hospitalier UniversitaireClermont-FerrandFrance

Personalised recommendations